CDC 494
Status:Completed
Phase:Open Label
Principal Investigator(s):Botswana Ministry of Health, CDC, Gilead
Objective:Follow-on trial of daily oral TDF/FTC in heterosexual men and women.
**Results presented in July 2015 show strong adherence, high drug levels and no HIV infections and support efforts to expand PrEP availability in the context of generalized epidemics in resource-limited settings.**
Start Date
End Date
none
none
Enrollment:0
Age range:
18 Years ↔
any
Population:Cisgender Men, Cisgender Women